专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

US20090326004A1 MUSCARINIC RECEPTOR ANTAGONISTS 审中-公开
标题翻译：肌肉受体拮抗剂
公开(公告)号：US20090326004A1
公开(公告)日：2009-12-31
申请号：US12473481
申请日：2009-05-28
申请人： Naresh KUMAR , Jitendra A. SATTIGERI , Shelly AERON , Malvika GARG , Abhijit RAY , Suman GUPTA , Shivani MALHOTRA , Raj Kumar SHIRUMALLA
发明人： Naresh KUMAR , Jitendra A. SATTIGERI , Shelly AERON , Malvika GARG , Abhijit RAY , Suman GUPTA , Shivani MALHOTRA , Raj Kumar SHIRUMALLA
IPC分类号： A61K31/439 , C07D453/02 , A61P1/06
CPC分类号： C07D453/02
摘要： The present invention relates generally to muscarinic receptor antagonist, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and the method for treating diseases mediated through muscarinic receptors. Also provided herein are pharmaceutical composition comprising one or more muscarinic receptor antagonists and at least one other active ingredients include, but are not limited to, corticosteroids, beta agonists, leukotriene antagonists, 5-lipoxygenase inhibitors, anti-histamines, antitussives, dopamine receptor antagonists, chemokine inhibitors, p38 MAP Kinase inhibitors, and PDE-IV inhibitors.
摘要翻译：本发明一般涉及毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。本发明还涉及制备所公开的化合物的方法，含有所公开的化合物的药物组合物和用于治疗通过毒蕈碱受体介导的疾病的方法。本文还提供包含一种或多种毒蕈碱受体拮抗剂的药物组合物，并且至少一种其它活性成分包括但不限于皮质类固醇，β激动剂，白细胞三烯拮抗剂，5-脂氧合酶抑制剂，抗组胺药，止咳药，多巴胺受体拮抗剂，趋化因子抑制剂，p38 MAP激酶抑制剂和PDE-IV抑制剂。

42. 发明授权

US07544708B2 Azabicyclo derivatives as muscarinic receptor antagonists 失效
标题翻译：偶氮二环衍生物作为毒蕈碱受体拮抗剂
公开(公告)号：US07544708B2
公开(公告)日：2009-06-09
申请号：US10520572
申请日：2003-04-11
申请人： Mohammad Salman , Anita Mehta , Pakala Kumara Savithru Sarma , Shankar Jayram Shetty , Sankaranarayanan Dharmarajan , Naresh Kumar , Arundutt Vishwanatham Silamkoti , Anita Chugh
发明人： Mohammad Salman , Anita Mehta , Pakala Kumara Savithru Sarma , Shankar Jayram Shetty , Sankaranarayanan Dharmarajan , Naresh Kumar , Arundutt Vishwanatham Silamkoti , Anita Chugh
IPC分类号： A61K31/40 , C07D209/44
CPC分类号： C07D401/12 , C07D209/52 , C07D403/12 , C07D413/12 , C07D417/12
摘要： This invention generally relates to muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Specifically, the invention relates to derivatives of azabicyclo compounds, including, for example, 6-substituted azabicyclo[3.1.0] hexanes, and 2,4,6-trisubstituted derivatives. The invention also relates to pharmaceutical compositions containing the compounds and the methods of treating the diseases mediated through muscarinic receptors.
摘要翻译：本发明一般涉及毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。具体地，本发明涉及氮杂双环化合物的衍生物，包括例如6-取代的氮杂双环[3.1.0]己烷和2,4,6-三取代的衍生物。本发明还涉及含有化合物的药物组合物和通过毒蕈碱受体介导的疾病的治疗方法。

43. 发明授权

US07399779B2 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists 失效
标题翻译：用作毒蕈碱受体拮抗剂的3,6-二取代的氮杂双环[3.1.0]己烷衍生物
公开(公告)号：US07399779B2
公开(公告)日：2008-07-15
申请号：US10520573
申请日：2002-07-08
申请人： Anita Mehta , Arundutt V. Silamkoti , Jang Bahadur Gupta
发明人： Anita Mehta , Arundutt V. Silamkoti , Jang Bahadur Gupta
IPC分类号： A61K31/403 , C07D209/52
CPC分类号： C07D401/12 , C07D209/52 , C07D403/12 , C07D413/12 , C07D417/12
摘要： This invention generally relates to the derivatives of novel 3,6 disubstituted azabicyclo[3.1.0]hexanes. The compounds of this invention are muscarinic receptor antagonists which are useful, inter-alia for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.
摘要翻译：本发明一般涉及新的3,6-二取代的氮杂双环[3.1.0]己烷的衍生物。本发明的化合物是毒蕈碱受体拮抗剂，其特别用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病。本发明还涉及含有本发明化合物的药物组合物和通过毒蕈碱受体介导的疾病的治疗方法。

44. 发明授权

US07241885B2 Process for the isolation of crystalline imipenem 失效
标题翻译：分离结晶亚胺培南的方法
公开(公告)号：US07241885B2
公开(公告)日：2007-07-10
申请号：US10478624
申请日：2002-05-20
申请人： Yatendra Kumar , Neera Tewari , Ram Chander Aryan , Bishwa Prakash Rai
发明人： Yatendra Kumar , Neera Tewari , Ram Chander Aryan , Bishwa Prakash Rai
IPC分类号： C07D477/20
CPC分类号： C07D477/20 , C07D477/02
摘要： The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity comprising the steps of treating an aqueous solution containing imipenem with an organic solvent, wherein the imipenem is not lyophilized; and isolating the pure crystalline imipenem monohydrate from the reaction mixture thereof.
摘要翻译：本发明涉及用于制备高纯度的亚胺培南的成本有效和工业上有利的方法，包括以下步骤：用有机溶剂处理含有亚胺培南的水溶液，其中亚胺培南不被冻干; 并从其反应混合物中分离纯结晶亚胺培南一水合物。

45. 发明申请

US20070135508A1 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists 失效
标题翻译： 3,6-二取代的氮杂双环己烷衍生物作为毒蕈碱受体拮抗剂
公开(公告)号：US20070135508A1
公开(公告)日：2007-06-14
申请号：US10552502
申请日：2003-04-10
申请人： Anita Mehta , Bruhaspathy Miriyala , Arundutt Silamkoti , Jang Gupta
发明人： Anita Mehta , Bruhaspathy Miriyala , Arundutt Silamkoti , Jang Gupta
IPC分类号： A61K31/403 , C07D405/02
CPC分类号： C07D209/52
摘要： The present invention relates to a radio telephony network (1) supporting at least one link of a radio channel (6) for a packet data transmission service. The radio telephony network (1) comprises a plurality of network controllers (RNC). Each network controller (RNC) is connected, via an interface Iub, to at least one base radio station (B-node) supervising at least one macrocell (5a). The radio telephony network (1) additionally comprises at least one base radio microstation (B1-micronode) connected to the network controller (RNC) via an interface Iub of the same type as that connecting the base radio station (B-node) to said controller. The base radio microstation (B1 micronode) supervises at least one microcell (5b) incorporated in at least one macrocell (5a). The base radio microstation (B1-micronode) provides the packet data transmission service in the microcell (5b) on the link of the radio channel (6).
摘要翻译：本发明涉及支持用于分组数据传输服务的无线电信道（6）的至少一个链路的无线电电话网络（1）。无线电电话网络（1）包括多个网络控制器（RNC）。每个网络控制器（RNC）经由接口Iub连接到监督至少一个宏小区（5a）的至少一个基站无线电台（B节点）。无线电电话网络（1）还包括经由与将基站无线电台（B节点）连接到所述网络控制器（RNC）的相同类型的接口Iub连接到网络控制器（RNC）的至少一个基站无线电微站（B1微米）控制器。基站无线电微型站（B1微处理器）监督并入至少一个宏小区（5a）中的至少一个微小区（5b）。基站无线电微站（B1-micronode）在无线电信道（6）的链路上的微小区（5b）中提供分组数据传输服务。

46. 发明授权

US07078534B2 Process for the preparation of crystalline N-formimidoyl thienamycin monohydrate (imipenem monohydrate) 失效
标题翻译：制备结晶N-甲脒基硫霉素一水合物（亚胺培南一水合物）的方法
公开(公告)号：US07078534B2
公开(公告)日：2006-07-18
申请号：US10415633
申请日：2001-11-05
申请人： Yatendra Kumar , Neera Tewari , Ran Chander Aryan , Bishwa Prakash Rai , Seema Ahuja
发明人： Yatendra Kumar , Neera Tewari , Ran Chander Aryan , Bishwa Prakash Rai , Seema Ahuja
IPC分类号： C07D209/32
CPC分类号： C07D477/20
摘要： The present invention relates to a cost effective and commercially viable process for the preparation of crystalline N-formimidoyl thienamycin monohydrate (Imipenem monohydrate) of Formula I.
摘要翻译：本发明涉及一种用于制备式I的结晶N-甲脒基硫霉素一水合物（亚胺培南一水合物）的成本有效和商业可行的方法。

47. 发明授权

US06919450B2 Process for the preparation of benazepril 失效
标题翻译：制备贝那普利的方法
公开(公告)号：US06919450B2
公开(公告)日：2005-07-19
申请号：US10472811
申请日：2002-03-14
申请人： Rajest Kumar Thaper , Yatendra Kumar , Shantanu De , S.M. Dileep Kumar
发明人： Rajest Kumar Thaper , Yatendra Kumar , Shantanu De , S.M. Dileep Kumar
IPC分类号： C07D223/16 , A61K20060101 , A61K31/55 , C07C303/00 , C07C303/28 , C07C307/00 , C07C309/00 , C07C309/65 , C07C311/00 , C07D223/04 , C07D487/00 , C07D491/00 , C07D498/00 , C07D513/00
CPC分类号： C07C303/28 , C07D223/16 , C07C309/65
摘要： The present invention relates to an improved process for the preparation of trifluoromethanesulfonic ester of ethyl (R)-2-hydroxy-4-phenylbutyrate, referred to here as triflate in structural Formula I, and to the use of this compound as intermediate for the preparation of ACE (Angiotensin Converting Enzyme) inhibitor, benazepril.
摘要翻译：本发明涉及制备（R）-2-羟基-4-苯基丁酸乙酯的三氟甲磺酸酯的改进方法，这里称为结构式I中的三氟甲磺酸酯，以及该化合物作为制备中间体的用途的ACE（血管紧张素转换酶）抑制剂贝那普利。

48. 发明授权

US5696275A Process for the manufacture of pharmaceutical grade ranitidine base 失效
标题翻译：制造药物级雷尼替丁碱的方法
公开(公告)号：US5696275A
公开(公告)日：1997-12-09
申请号：US265308
申请日：1994-06-24
申请人： Jag Mohan Khanna , Naresh Kumar , Brij Khera , Purna Chandra Ray
发明人： Jag Mohan Khanna , Naresh Kumar , Brij Khera , Purna Chandra Ray
IPC分类号： C07D307/52
CPC分类号： C07D307/52
摘要： A process for the manufacture of pharmaceutical grade ranitidine base(N-�2-��5-(Dimethylamino)methyl!-2-furanyl!methyl!thio!ethyl-N'-methyl-2-nitro-1, 1-ethenediamine), is described. In-vitro and in-vivo pharmacological studies and acute toxicity studies indicate that it is as active and as safe as Form 2 ranitidine hydrochloride.
摘要翻译：制备药物级雷尼替丁碱（N- [2 - [[[5-（二甲基氨基）甲基] -2-呋喃基]甲基]硫基]乙基-N'-甲基-2-硝基-1,1- 乙烯二胺）。体外和体内药理学研究和急性毒性研究表明，它与盐酸盐酸雷尼替丁的活性和安全性一样。

49. 发明申请

US20150246899A1 PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 审中-公开
标题翻译：制备DABIGATRAN ETEXILATE或其药学上可接受的盐的方法
公开(公告)号：US20150246899A1
公开(公告)日：2015-09-03
申请号：US14430303
申请日：2013-09-30
申请人： RANBAXY LABORATORIES LIMITED
发明人： Anandam Vempali , Sudhir Singh Sanwal , Balaguru Murugesan , Swargam Sathyanarayana , Rajesh Kumar Thaper , Mohan Prasad
IPC分类号： C07D401/12 , C07C53/48 , C07C53/10 , C07D213/75 , C07C309/19
CPC分类号： C07D401/12 , C07C53/10 , C07C53/48 , C07C309/19 , C07D213/75
摘要： The present invention relates to a process for the preparation of dabigatran etexilate. The present invention also relates to trifluoroacetate salt of dabigatran etexilate and a process for its preparation. The present invention further relates to crystalline Form I and crystalline Form II of trifluoroacetate salt of dabigatran etexilate and processes for their preparation. The present invention further relates to a process for the preparation of pharmaceutically acceptable salts, including methanesulfonate salt, of dabigatran etexilate.
摘要翻译：本发明涉及制备达比加群酯的方法。本发明还涉及达比加群酯的三氟乙酸盐及其制备方法。本发明还涉及达比加群酯的三氟乙酸盐的晶型I和结晶形式II及其制备方法。本发明还涉及制备达比加群酯的药学上可接受的盐，包括甲磺酸盐的方法。

50. 发明授权

US08916713B2 Process for the preparation of febuxostat 有权
标题翻译：制备febustostat的方法
公开(公告)号：US08916713B2
公开(公告)日：2014-12-23
申请号：US13812066
申请日：2011-07-15
申请人： Pranab Chatterjee , Asok Nath , Sarbjot Singh Sokhi , Mohan Prasad
发明人： Pranab Chatterjee , Asok Nath , Sarbjot Singh Sokhi , Mohan Prasad
IPC分类号： C07D277/56
CPC分类号： C07D277/56
摘要： An improved and efficient process for the preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid (febuxostat) that is substantially free from amide by-product is provided.
摘要翻译：提供了一种改进和有效的制备基本上不含酰胺副产物的2- [3-氰基-4-（2-甲基丙氧基）苯基] -4-甲基噻唑-5-羧酸（febustostat）的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式